RICHMOND, Calif., April 8, 2021 /PRNewswire/ — DiaCarta Inc., a precision molecular diagnostics firm with proprietary applied sciences for the event of novel liquid biopsy oncology checks, introduced immediately the publication of a examine in Nature Scientific Stories that demonstrates that DiaCarta’s cfDNA biomarker algorithm may perform as a prognostic biomarker and efficacy predictor for non-small cell lung most cancers (NSCLC) sufferers.1
The paper entitled, “Kinetics of Plasma cfDNA Predicts Medical Response in Non-Small Cell Lung Most cancers Sufferers”1 evaluated the utility of a plasma cell-free DNA (cfDNA) algorithm of pre-chemotherapy (CT) and first cycle post-CT as a prognostic biomarker and efficacy predictor of CT, in NSCLC sufferers utilizing DiaCarta’s proprietary QuantiDNA™ cfDNA check. The biomarker offers real-time analysis of the remedy and permits adjustment of therapy at early stage of the remedy if crucial.
The QuantiDNA™ cfDNA check is used to quantify the overall quantity of cfDNA immediately from a plasma pattern whereas the affected person is present process most cancers remedy. The check is extremely correct as a result of it makes use of DiaCarta’s extremely delicate SuperbDNA™ know-how, a particularly dependable and signal-specific amplification platform that permits quantitative detection of particular nucleic acid sequences immediately from the supply. Beforehand, the identical check, often called RadTox™ check when used for radiotherapy toxicity measurement, was additionally used to exhibit the cfDNA algorithm of the pre- and post-radiotherapy affected person samples is a possible biomarker for radiotherapy security measurement.2
Dr. Steven Eric Finkelstein, MD, DABR, FACRO, Editor-in-Chief, Modern Radiation Oncology stated that “the RadTox™ check has the potential to satisfy an essential unmet medical want in most cancers remedy by enabling the direct monitoring of cell demise inside hours after a most cancers therapy; thus, they’ll predict tumor response, no matter tumor sort, and in postoperative sufferers predict aspect impact severity. This distinctive method has the potential to supply a quick, cost-effective quantitation of liquid biopsy circulating DNA in most cancers sufferers earlier than and after remedy, offering affected person info for early scientific choice making.”
DiaCarta is initiating a large-scale scientific growth program, which is able to monitor cfDNA ranges to find out early therapy outcomes of systemic remedy in all varieties of stage four most cancers. As well as, DiaCarta will proceed to guage cfDNA as a predictive marker for early tissue toxicity from varied most cancers therapies, to facilitate early chemo and/or radiation remedy dose changes. As soon as in depth scientific validation is accomplished, DiaCarta will pursue regulatory approval to market the RadTox™ check equipment worldwide for a number of most cancers indications.
“This pivotal examine demonstrates the utility of DiaCarta’s developmental pipeline,” stated Ram Vairavan, Ph.D., Senior Vice President of Enterprise Growth at DiaCarta, Inc. “This information shall be used to information a big scientific growth program. The development of this mission has the potential to change into a ‘first-in-class,’ class IVD (in vitro diagnostic) check within the subject of most cancers remedy. Though this new examine was targeted on lung most cancers, the RadTox™ cfDNA check has additionally been utilized to many different most cancers sufferers together with colon, breast, pancreatic most cancers, and many others. and up to now two years DiaCarta has examined over 100,000 samples globally, suggesting a broader software for this know-how.”
About DiaCarta Inc.
DiaCarta is a molecular diagnostics firm that has developed progressive applied sciences that transforms affected person care by offering efficient precision diagnostics utilizing liquid biopsy. Along with its FDA EUA authorized QuantiVirusTM SARS-CoV-2 Check, DiaCarta gives a variety of testing companies, from single-gene QClamp® qPCR checks to its OptiSeq™ XNA-NGS panels. The corporate is properly positioned as a pacesetter within the new ‘liquid biopsy’ IVD (in vitro diagnostic) subject with high-precision detection of cfDNA. Its novel XNA know-how offers excessive stage of sensitivity because it binds to the wild-type sequence and allows solely the mutant goal sequence to get amplified. Utilizing this know-how, the corporate has developed its extremely delicate ColoScape™ early detection Colorectal Most cancers check utilizing blood. Powered by its SuperbDNA™ know-how that gives excessive stage of detection because it amplifies the sign and requires no RNA/DNA extraction or amplification, the corporate has developed its revolutionary RadTox™ check that personalizes radiation remedy, mitigates opposed occasions and enhances affected person care. Primarily based in Richmond, California the corporate is ISO licensed, GMP-compliant and gives CLIA licensed laboratory companies to its prospects. www.diacarta.com
- Kinetics of Plasma cfDNA Predicts Medical Response in Non-Small Cell Lung Most cancers Sufferers, Nature Scientific Stories 11, Article No: 7633; Pages 12; MS code 85797; Dispatch 8-302021.
- Circulating Cell-Free DNA Correlates with Physique Integral Dose and Radiation Modality in Prostate Most cancers Int J Half Ther 2020 Sep 15;7(2):21-30. doi: 10.14338/IJPT-20-00033.1. eCollection Fall 2020.
Richard Model, CFO, DiaCarta
Olipriya Das, Ph.D.,Russo Companions
SOURCE DiaCarta Inc.